LKFT — Lakefront Biotherapeutics NV Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapSuper Stock

Annual income statement for Lakefront Biotherapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	C2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	539	277	240	276	1,112
Cost of Revenue
Gross Profit	537	—	—	241	1,083
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	704	408	328	464	817
Operating Profit	-166	-131	-88.3	-188	295
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-123	-70.8	5.63	-3.08	301
Provision for Income Taxes
Net Income After Taxes	-125	-71.4	-3.99	-1.28	319
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-103	-218	212	74.1	321
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-103	-218	212	74.1	321
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.78	-0.823	0.159	0.33	7.52
Dividends per Share